Polycystic ovary syndrome sits at the intersection of insulin resistance, chronic low-grade inflammation and oxidative stress. That is a profile an antioxidant carotenoid might plausibly affect, and unlike most astaxanthin topics, this one has actual randomized human trials behind it.
It has two. Both are worth reading in detail, and both come with a limitation that is rarely mentioned when they are cited.
Key Takeaways
- A triple-blind randomized trial in 58 infertile women with PCOS used 12 mg per day (2 x 6 mg) for 8 weeks and reported significant improvements in fasting blood sugar, HOMA-IR, malondialdehyde, LDL-C and total antioxidant capacity [1].
- After adjusting for baseline age, BMI and biochemical values, QUICKI and fasting insulin lost significance. The authors reported this rather than omitting it [1].
- A second randomized double-blind trial in 56 women with PCOS at the same 12 mg dose found reduced TNF-alpha (p = 0.009), IL-18 (p = 0.003) and IL-6 (p = 0.013), plus reduced expression of ER stress genes CHOP, XBP1, ATF4 and DR5 [2].
- In that second trial, GRP78 was only marginal (p = 0.051) and ATF6 did not reach significance [2].
- Both trials come from the same research group and the same institution, so this is one research program rather than independent replication.
- Neither trial measured pregnancy, ovulation or live birth. This is metabolic and inflammatory data, not fertility data.
Why PCOS Is A Reasonable Place To Look
PCOS is not only a reproductive condition. Insulin resistance is present in a large share of women with the diagnosis regardless of body weight, and the syndrome carries a chronic pro-inflammatory and pro-oxidative profile. Endoplasmic reticulum stress, the cellular response that fires when misfolded proteins accumulate, has been implicated in the apoptotic and inflammatory signaling seen in PCOS.
Astaxanthin has documented antioxidant and anti-inflammatory activity. So unlike the case for, say, weight loss, there is a coherent reason to run the trial. Two groups did.
Trial One: Metabolic And Oxidative Markers
The first is a 2023 triple-blind randomized clinical trial published in Phytotherapy Research [1]. Fifty-eight infertile women with diagnosed PCOS were randomly assigned to astaxanthin at 2 x 6 mg per day or placebo for 8 weeks. Blood was drawn before and after. The team measured fasting insulin, fasting blood glucose, oxidative stress markers (malondialdehyde, superoxide dismutase, total antioxidant capacity), lipid panels, several calculated insulin resistance indices, and blood pressure.
After 8 weeks the astaxanthin group showed significant reductions in:
- Fasting blood sugar
- HOMA-IR (a standard insulin resistance index)
- Fasting insulin
- Malondialdehyde, a lipid peroxidation marker
- LDL cholesterol
- The total cholesterol to HDL-C ratio
And significant increases in total antioxidant capacity, HDL-C and QUICKI, another insulin sensitivity index [1].
Then comes the part that makes this a good trial. The authors re-ran the analysis adjusted for baseline age, BMI and baseline biochemical parameters. After adjustment, QUICKI and fasting insulin were no longer significant [1]. The other findings survived. Blood pressure, which was measured, does not appear among the significant outcomes at all, a point covered further in our blood pressure article.
Reporting which of your own results dissolved under adjustment is not obligatory and it is not flattering. It is a marker of a trial worth taking seriously.
Trial Two: Inflammation And ER Stress
The second trial, published in 2024, was a randomized double-blind study in 56 women with PCOS aged 18 to 40, again at 12 mg per day for 8 weeks [2]. This one went after inflammatory signaling and endoplasmic reticulum stress rather than glucose handling.
Serum inflammatory markers measured by ELISA fell significantly against placebo:
- TNF-alpha (p = 0.009)
- IL-18 (p = 0.003)
- IL-6 (p = 0.013)
Gene expression in peripheral blood mononuclear cells, measured by real-time PCR, showed reduced expression of CHOP (p = 0.008), XBP1 (p = 0.002), ATF4 (p = 0.038) and DR5 (p = 0.016) [2]. Two markers did not clear the bar: GRP78 was marginal at p = 0.051, and ATF6 did not reach significance (p = 0.067) [2].
Again, the null results are stated rather than buried. A trial that reports four significant genes and two that missed is more believable than one reporting six for six.
The Limitation Almost Nobody Mentions
Here is the thing to hold onto. These are not two independent confirmations of each other. Both trials share lead authorship, come out of the same institution in Tehran, use the same 12 mg dose, the same 8 week duration, and near-identical sample sizes in the same patient population over an overlapping period.
That is one research program producing two papers on different endpoints, which is normal and legitimate science. It is just not what people usually mean when they say a finding has been replicated. Independent replication means a different team, in a different population, finding the same thing. That has not happened yet for astaxanthin in PCOS.
Sample sizes are also small. Fifty-eight and fifty-six participants are reasonable for biomarker endpoints and far too small to detect anything about clinical outcomes.
What These Trials Did Not Measure
This is the gap that matters most for anyone considering astaxanthin for PCOS. Neither trial measured:
- Ovulation rate
- Menstrual cycle regularity as a primary endpoint
- Pregnancy or live birth
- Androgen levels or clinical hyperandrogenism (hirsutism, acne)
- Anything beyond 8 weeks
The first trial enrolled specifically infertile women with PCOS and still reported metabolic and oxidative outcomes rather than fertility outcomes [1]. So if you are considering astaxanthin because you are trying to conceive, understand that the trials in this population did not test that question.
Our male fertility article covers the parallel literature in men, where semen parameter data exists and a 2026 meta-analysis found no significant human improvement.
How To Read This If You Have PCOS
The reasonable summary: two small randomized trials at 12 mg per day for 8 weeks report improvements in insulin resistance markers, lipid ratios, oxidative stress markers and inflammatory cytokines in women with PCOS. Those are real findings from properly blinded trials that reported their own null results honestly.
They are also small, from a single research group, limited to biomarkers, and silent on the outcomes most women with PCOS actually care about. Astaxanthin is not a treatment for PCOS on this evidence, and it is not a substitute for metformin, inositol, lifestyle intervention or anything else your clinician has recommended.
The 12 mg dose used in both trials is at the upper end of common consumer softgels, which usually run 4 to 12 mg. See our dosage guide for context, and our pregnancy and breastfeeding review if conception is the goal, because that changes the safety calculus. Talk to the clinician managing your PCOS before adding anything.
Frequently Asked Questions
Does astaxanthin help PCOS?
Two small randomized trials at 12 mg per day for 8 weeks reported improvements in insulin resistance markers, LDL cholesterol, oxidative stress markers and inflammatory cytokines in women with PCOS. Both trials came from the same research group, both were under 60 participants, and neither measured ovulation, pregnancy or androgen levels.
What dose of astaxanthin was used in the PCOS trials?
Both trials used 12 mg per day for 8 weeks. The first gave it as 2 x 6 mg. That sits at the upper end of typical consumer softgels, which commonly range from 4 to 12 mg.
Has astaxanthin been shown to improve fertility in PCOS?
No. The first trial enrolled infertile women with PCOS but reported metabolic and oxidative stress outcomes, not ovulation, pregnancy or live birth. No trial has tested astaxanthin against a fertility endpoint in PCOS.
Are the PCOS trials independent of each other?
Not really. They share lead authorship and institution, use the same 12 mg dose and 8 week duration, and enrolled similar numbers from the same population over an overlapping period. That is one research program with two papers, not independent replication by a separate team.
Can astaxanthin replace metformin or inositol for PCOS?
No. The available evidence covers biomarkers over 8 weeks in fewer than 120 women total. It does not support astaxanthin as a treatment for PCOS or as a replacement for anything your clinician has prescribed.
References
- Jabarpour M, Aleyasin A, Shabani Nashtaei M, Amidi F. Astaxanthin supplementation impact on insulin resistance, lipid profile, blood pressure, and oxidative stress in polycystic ovary syndrome patients: A triple-blind randomized clinical trial. Phytother Res. 2024;38(1):321-330. PMID 37874168
- Jabarpour M, et al. Randomized clinical trial of astaxanthin supplement on serum inflammatory markers and ER stress-apoptosis gene expression in PBMCs of women with PCOS. J Cell Mol Med. 2024;28(14):e18464. PMID 39036884
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
